Synergism between bosutinib (SKI-606) and the Chk1 inhibitor (PF-00477736) in highly imatinib-resistant BCR/ABL⁺ leukemia cells.

@article{Nguyen2015SynergismBB,
  title={Synergism between bosutinib (SKI-606) and the Chk1 inhibitor (PF-00477736) in highly imatinib-resistant BCR/ABL⁺ leukemia cells.},
  author={Tri K Nguyen and Elisa Hawkins and Akhil Kolluri and Maciej Kmieciak and Haeseong Park and Hui Lin and Steven Grant},
  journal={Leukemia research},
  year={2015},
  volume={39 1},
  pages={65-71}
}
Interactions between the dual BCR/ABL and Src inhibitor bosutinib and the Chk1 inhibitor PF-00477736 were examined in BCR/ABL(+) leukemia cells, particularly imatinib-resistant cells, including those with the T315I mutation. Bosutinib blocked PF-00477736-induced ERK1/2 activation and sharply increased apoptosis in association with Mcl-1 inhibition, p34(cdc2) dephosphorylation, BimEL up-regulation, and DNA damage in imatinib-resistant CML or Ph(+) ALL cell lines. Inhibition of Src or MEK1 by… CONTINUE READING

From This Paper

Figures, tables, results, connections, and topics extracted from this paper.
3 Extracted Citations
0 Extracted References
Similar Papers

Citing Papers

Publications influenced by this paper.

Similar Papers

Loading similar papers…